A novel beta-lactam-containing combination therapy for the shortening of Buruli ulcer treatment - Phase III evaluation in West Africa
This is a two stage application process. We passed Stage 1 and just submitted Stage 2. If successful, with expected start date January 1, 2021 and a duration of 48 months.
Acronym:
BLMs4BU
Author:
Ramón García, Santiago
Principal researcher:
Santiago Ramón Garcia
Managing entity:
OPE - Universidad de Zaragoza
Scope:
Internacional
Entidades participantes:
Universidad de Zaragoza (coordinador)
Kwame Nkrumah University of Science and Technology (KNUST)
Ghana Health Service
Programme national de lutte contre l'ulcère de Buruli, Bénin
Programme National des Maladies Tropicales Negligées, Togo
Programme National de Lutte Contre l'Ulcère de Buruli, Côte d'Ivoire
Anesvad Foundation
Fondation Raoul Follereau (FRF)
Deutsche Lepra- und Tuberkulosehilfe e. V. (DAHW)
Instituto de Salud Carlos III
GlaxoSmithKline Investigación y Desarrollo (GSK I+D)
This is a two stage application process. We passed Stage 1 and just submitted Stage 2. If successful, with expected start date January 1, 2021 and a duration of 48 months.